Drug intelligence / Profile preview

1C11

Development stage: Preclinical
Lead developer: Ginkgo Bioworks
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intraperitoneal

Overview

1C11 is a monoclonal antibody developed by Emory University. It is part of a cocktail, along with 1C3, designed to target filoviruses, including Ebola and Sudan viruses, as a medical countermeasure. Ginkgo Bioworks is involved in a project with BARDA to innovate and scale the biomanufacturing of this antibody cocktail to strengthen U.S. biomanufacturing resilience and reduce production costs.

Targets

PYG (Glycogen phosphorylase)

Beyond the preview

Go deeper on 1C11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1C11.

Explore the full profile